GLUCAGON/GLP-1 AGONISTS FOR THE TREATMENT OF OBESITY

Abstract

This disclosure provides GLP-1 /glue agon agonist peptides for the treatment of metabolic diseases, *e.g.*, obesity.

[Figure 1]